Nanobiotix S.A.

Nanobiotix S.A. filed a Form 6-K reporting its voting rights and share capital as of September 30, 2026. The company disclosed 50,967,610 shares outstanding and a total of 54,729,543 voting rights, with 54,707,425 being exercisable. This filing is a routine disclosure of corporate information.

Nanobiotix S.A. disclosed its share capital and voting rights as of June 30, 2026. The company reported 50,825,682 shares outstanding, with total theoretical voting rights amounting to 54,486,890 and total exercisable voting rights at 54,464,772.

Nanobiotix S.A. announced an update on its voting rights and shares capital as of May 31, 2026, in accordance with French commercial and financial regulations. The company reported 50,807,903 shares outstanding. The total theoretical voting rights stood at 54,304,858, with 54,282,740 exercisable voting rights.

Nanobiotix provided its first-quarter 2026 operational and financial update, highlighting a successful follow-on offering in May 2026 that raised approximately €86.1 million in gross proceeds. This funding, combined with €42.1 million in cash as of March 31, 2026, is projected to support operations into 2029. The company also reported positive new data from its Phase 2 CONVERGE study for JNJ-1900 (NBTXR3) in NSCLC, showing high response rates, and announced FDA acceptance of a protocol amendment to accelerate the pivotal NANORAY-312 study.

Nanobiotix S.A. announced its inclusion in the Euronext Tech Leaders segment and Euronext Tech Leaders Index. This initiative by Euronext aims to enhance the visibility and attractiveness of Europe's leading and high-growth technology companies among international investors. The company's CEO, Laurent Levy, stated that this inclusion recognizes Nanobiotix's progress and the broader potential of physics-based innovation in healthcare.

Nanobiotix S.A. announced the closing of its Global Offering, which included a U.S. Offering of American Depositary Shares (ADSs) and a European Offering of Ordinary Shares, alongside Pre-Funded Warrants. The company also confirmed the exercise of the U.S. Over-Allotment Option by the underwriters for additional ADSs. The offering is expected to close on or about May 26, 2026, raising capital for the company.

Nanobiotix S.A. announced the closing of its global offering, which included the full exercise of the underwriters' option for additional American Depositary Shares (ADSs). The offering generated approximately $100 million in aggregate gross proceeds. The company plans to allocate 50-60% of the net proceeds to advance its Nanoprimer and other platforms, 30-40% for general corporate purposes, and less than 10% for JNJ-1900 development. This capital raise is expected to fund the company's operations into 2029.

Nanobiotix announced that the underwriters of its global offering fully exercised their over-allotment option to purchase 33,805 additional American Depositary Shares (ADSs). This brings the total gross proceeds from the offering to approximately $100 million (€86.1 million). The company intends to use the net proceeds to advance its Nanoprimer and other platforms (50-60%), for general corporate purposes (30-40%), and to support the development of JNJ-1900 (NBTXR3) (<10%). The company believes these proceeds, combined with existing cash, will fund operations into 2029.

Nanobiotix announced the pricing of its oversubscribed global follow-on offering, expected to generate approximately $98.6 million (€85.0 million) in gross proceeds. The offering includes 225,373 American Depositary Shares (ADSs) at $38.98 per ADS in the U.S., and 1,959,289 Ordinary Shares and 345,099 pre-funded warrants (PFWs) at €33.60 per Ordinary Share and €33.57 per PFW in Europe. The company plans to use the net proceeds to advance its Nanoprimer and other platforms (50-60%), support JNJ-1900 development (less than 10%), and for general corporate purposes (30-40%), extending its cash runway into 2029.

Nanobiotix announced the resumption of trading of its ordinary shares on the regulated market of Euronext Paris as of 3:30 p.m. (Paris time) on May 21, 2026. Trading had been halted earlier in the day to allow for the confirmation of allocations to investors and the announcement of the pricing of a previously disclosed Global Offering. This offering comprises a public offering of American Depositary Shares (ADSs) in the United States and an offering of ordinary shares and pre-funded warrants to qualified investors in Europe and other countries.